The board of directors hereby convenes the Annual General Meeting of
at the Company’s premises, Ole Maaløes Vej 3, meeting room – M0.08 - Oxygen, DK-2200 Copenhagen N,
The agenda for the Annual General Meeting is as follows:
- ELECTION OF CHAIRMAN OF THE MEETING
- REPORT ON THE ACTIVITIES OF THE COMPANY IN THE PAST FINANCIAL YEAR
- PRESENTATION OF THE ANNUAL REPORT WITH AUDITORS' REPORT FOR ADOPTION
- RESOLUTION ON COVERING OF LOSSES IN ACCORDANCE WITH THE ADOPTED ANNUAL REPORT
- ELECTION OF MEMBERS TO THE BOARD OF DIRECTORS
- ELECTION OF THE COMPANY’S AUDITOR
- PROPOSALS FROM THE BOARD OF DIRECTORS AND SHAREHOLDERS
- Approval of the remuneration of the board of directors
- MISCELLANEOUS
Complete Proposals:
Re 1: Election of chairman of the meeting
The board of directors proposes that attorney-at-law Lars Lüthjohan be elected as the chairman of the general meeting.
Re 2: Report on the activities of the Company in the past financial year
An oral report on the activities of the Company in the past financial year will be presented. The board of directors proposes that the report is noted by the general meeting.
Re 3: Presentation of the annual report with auditors' report for adoption
The board of directors proposes that the Company's annual report with the auditors' report for the financial year 2023 is adopted. The annual report is available on the Company's website.
Re 4: Resolution on covering of losses in accordance with the adopted annual report
The board of directors proposes that the consolidated loss for the financial year 2023 of tDKK 38,377 is carried forward to the next financial year in accordance with the adopted annual report.
Re 5: Election of members to the board of directors
The board of directors currently consists of the following members:
Re 6: Election of the Company’s auditor
The board of directors proposes re-election of PricewaterhouseCoopers Statsautoriseret Revisionspartnerselskab, CVR no. 39 29 64 38, as the Company's auditor.
Re 7.1: Proposal from the board of directors to approve the remuneration of the board of directors for the financial year 2024
The board of directors proposes that the board of directors shall receive remuneration for the financial year 2024 to be paid out at the annual general meeting of 2025.
The proposed remuneration is as follows:
DKK payment for the year 2024 | Warrants, up to | |
Chairman | 280,000 | 0 |
Vice Chairman | 200,000 | 0 |
Board member | 100,000 | 0 |
New board members may be offered | 80,000 | 7,500 |
Re 8: Miscellaneous
Voting by proxy or correspondence
The shareholders may vote by proxy or correspondence for the Annual General meeting. Shareholders may grant proxy to a named third party or to the Board of Directors. Alternatively, shareholders may cast their vote in advance of the meeting (vote by correspondence). A proxy and voting correspondence form can be found on the Company’s website (www.fluoguide.com).
Proxy
Voting by proxy shall be submitted by returning the proxy and voting by correspondence form, duly completed, and signed, by email to ole@fluoguide.com. Proxies shall be submitted no later than
Voting by correspondence
Any shareholder who wishes to vote by mail shall submit the proxy and voting by correspondence form, duly completed and signed, by email to ole@fluoguide.com. Votes by correspondence must be submitted no later than 16.00 CET on
Information:
Adoption requirements
The proposals may be adopted by a simple majority of the votes.
Share capital and voting rights
The Company's share capital is nominal
A shareholder's right to attend and vote at the Annual General meeting is determined at the registration date,
Shareholders who are entitled to attend the Annual General meeting and who wish to attend the Annual General meeting must request an admission card no later than
The following documents are available at the Company's premises and website (www.fluoguide.com) from
- Notice of Annual General Meeting
- Proxy and voting by correspondence form
- Annual report with auditors' report for 2023
For further information, please contact:
+45 40 84 28 37
IR@fluoguide.com
Ole@fluoguide.com
Certified Adviser:
About
The Company has published strong results from phase II trials demonstrating the efficacy of FG001 as well as showing it was well tolerated and safe from clinical trials in patients undergoing surgery to remove aggressive brain (high-grade glioma), head & neck and lung cancers.
Based on this strong foundation,
Read more about FluoGuide’s pipeline, technology, and upcoming events on www.fluoguide.com
Appendix 1 – see below.
Appendix 1
Roger is co-founder and senior advisor at Segulah Medical Acceleration, a Scandinavian growth equity investment firm. Prior to SMA, Roger worked as an international investment banker for 25 years, with a focus on healthcare for the last 18 years. Roger is recognised as a leading financial and M&A advisor in the international life science sector. Roger has a global network of contacts, across many of the world’s largest healthcare corporation and smaller start-ups as well, ensuring access to relevant decision makers at potential partners. Roger holds a MSc in Business Administration and Economics from the
© Modular Finance, source